Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review.
Maria Cecília de AragãoRodrigo Fedatto BeraldoMariana Barros MarcondesJaqueline Ribeiro de BarrosGiedre Soares Prates HerreriasRogério Saad HossneJulio Pinheiro BaimaLigia Yukie SassakiPublished in: Medicine (2022)
Our case suggests that the use of infliximab is safe in pregnancy, and drug discontinuation could be considered from the 24th week of pregnancy onward to reduce placental transfer to the newborn in patients at low risk of relapse. Vaccines with live attenuated organisms should be delayed for at least 6 months or until the serum level of the medication is undetectable.
Keyphrases
- end stage renal disease
- preterm birth
- ulcerative colitis
- ejection fraction
- newly diagnosed
- rheumatoid arthritis
- healthcare
- pregnancy outcomes
- peritoneal dialysis
- prognostic factors
- clinical trial
- adverse drug
- randomized controlled trial
- stem cells
- pregnant women
- gram negative
- mesenchymal stem cells
- patient reported outcomes
- multidrug resistant
- patient reported